Xenon Pharmaceuticals (XENE) Tops Q3 EPS by 15c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Xenon Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
November 5, 2019 4:01 PM ESTIn Addition to Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy, Company Advances Epilepsy Programs and Anticipates Initiating Pediatric Clinical Trials in KCNQ2 (XEN496) and SCN8A (XEN901) Developmental and Epileptic Encephalopathies in 2020Â
XEN007 Phase 2 Proof-Of-Concept, Physician-Led Study Initiated in Pediatric Patients with  Treatment-Resistant Childhood Absence Epilepsy
Conference Call at 4:30 pm ET Today
BURNABY, British Columbia, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:... More
